Equities

Replimune Group Inc

Replimune Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.24
  • Today's Change0.16 / 1.44%
  • Shares traded652.48k
  • 1 Year change-36.96%
  • Beta1.2114
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform6
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Replimune Group Inc have a median target of 16.00, with a high estimate of 17.00 and a low estimate of 13.00. The median estimate represents a 42.48% increase from the last price of 11.23.
High51.4%17.00
Med42.5%16.00
Low15.8%13.00

Earnings history & estimates in USD

On Aug 08, 2024, Replimune Group Inc reported 1st quarter 2025 losses of -0.78 per share. This result exceeded the -0.85 consensus loss of the 8 analysts covering the company and under-performed last year's 1st quarter results by 4.00%.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate-1.79%
Replimune Group Inc reported annual 2024 losses of -3.24 per share on May 16, 2024.
Average growth rate-20.86%
More ▼

Revenue history & estimates in USD

Replimune Group, Inc. did not report revenues for the 1st quarter 2025. However, during the 1st quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Replimune Group, Inc. did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.